AR110405A1 - Compuestos - Google Patents

Compuestos

Info

Publication number
AR110405A1
AR110405A1 ARP170103598A ARP170103598A AR110405A1 AR 110405 A1 AR110405 A1 AR 110405A1 AR P170103598 A ARP170103598 A AR P170103598A AR P170103598 A ARP170103598 A AR P170103598A AR 110405 A1 AR110405 A1 AR 110405A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
group
independently selected
amino
Prior art date
Application number
ARP170103598A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
C4 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, C4 Therapeutics Inc filed Critical Hoffmann La Roche
Publication of AR110405A1 publication Critical patent/AR110405A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009Sachets, pouches characterised by the material or function of the envelope
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Reivindicación 1: Compuesto de fórmula (1), en la que R¹ se selecciona cada uno independientemente entre el grupo que consiste en i) amino, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) ciano, v) halógeno, vi) halógenoalquilo C₁₋₆, vii) halógenoalcoxi C₁₋₆, y viii) hidroxi; R² se selecciona cada uno independientemente entre el grupo que consiste en i) amino, ii) arilo sustituido con (R³)ₖ, iii) alquilo C₁₋₆, iv) alcoxi C₁₋₆, v) alquinilo C₂₋₆ sustituido con (R⁵)ₚ, vi) ciano, vii) halógeno, viii) halógenoalquilo C₁₋₆, ix) halógenoalcoxi C₁₋₆, x) heteroarilo sustituido con (R⁴)ₗ, xi) heterociclilo sustituido con (R⁷)ʳ y xii) hidroxi; R³ se selecciona cada uno independientemente entre el grupo que consiste en i) amino, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) ciano, v) halógeno, vi) halógenoalquilo C₁₋₆, vii) halógenoalcoxi C₁₋₆, y viii) hidroxi; R⁴ se selecciona cada uno independientemente entre el grupo que consiste en i) amino, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) ciano, v) halógeno, vi) halógenoalquilo C₁₋₆, vii) halógenoalcoxi C₁₋₆, viii) heterociclilo sustituido con (R⁸)ₛ, y ix) hidroxi; R⁵ se selecciona independientemente entre el grupo que consiste en i) heteroarilo sustituido con (R⁶)q, y ii) alquilo C₁₋₆; R⁶ se selecciona independientemente entre el grupo que consiste en i) amino, y ii) alquilo C₁₋₆; R⁷ se selecciona independientemente entre el grupo que consiste en i) amino, y ii) alquilo C₁₋₆; R⁸ se selecciona independientemente entre el grupo que consiste en i) amino, y ii) alquilo C₁₋₆; Het es heteroarilo; k es 0, 1, 2 ó 3; l es 0, 1 ó 2; n es 0, 1, 2 ó 3; m es 0, 1 ó 2; p es 0, 1 ó 2; q es 0, 1 ó 2; r es 0, 1 ó 2; s es 0, 1 ó 2; o una sal farmacéuticamente aceptable del mismo.
ARP170103598A 2016-12-22 2017-12-20 Compuestos AR110405A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16206394 2016-12-22

Publications (1)

Publication Number Publication Date
AR110405A1 true AR110405A1 (es) 2019-03-27

Family

ID=57777430

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103598A AR110405A1 (es) 2016-12-22 2017-12-20 Compuestos

Country Status (7)

Country Link
US (2) US10882848B2 (es)
EP (1) EP3558967B1 (es)
JP (1) JP7076453B2 (es)
CN (1) CN110325528B (es)
AR (1) AR110405A1 (es)
TW (1) TW201834651A (es)
WO (1) WO2018115218A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101911090B1 (ko) * 2011-12-27 2018-10-25 두산인프라코어 주식회사 인양력 증대 자세교정 장치
US10266517B2 (en) 2014-12-23 2019-04-23 Dana-Farber Cancer Institute, Inc. Pyrimidines as EGFR inhibitors and methods of treating disorders
AU2018276441B2 (en) * 2017-06-02 2022-04-28 F. Hoffmann-La Roche Ag Compounds
EP3755689B1 (en) 2018-02-20 2023-12-06 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
KR20210025535A (ko) * 2018-06-29 2021-03-09 에프. 호프만-라 로슈 아게 화합물
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
EP3935050A4 (en) 2019-03-06 2023-01-04 C4 Therapeutics, Inc. HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT
US20220315592A1 (en) * 2019-06-21 2022-10-06 Hoffmann-La Roche Inc. Egfr inhibitor for the treatment of cancer
AR120799A1 (es) * 2019-12-20 2022-03-16 Hoffmann La Roche 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
MX2022007659A (es) * 2019-12-20 2022-07-19 C4 Therapeutics Inc Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr).
AR120800A1 (es) * 2019-12-20 2022-03-16 Hoffmann La Roche Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr
CA3167899A1 (en) 2020-02-14 2021-08-19 Xiangyong LIU Quinolyl phosphine oxide compound, and composition and application thereof
AR124170A1 (es) * 2020-12-01 2023-02-22 Hoffmann La Roche Nuevos derivados de indazol acetileno
JP2023553830A (ja) * 2020-12-01 2023-12-26 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
US20240059692A1 (en) * 2020-12-01 2024-02-22 Hoffmann-La Roche Inc. New indazole derivatives
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE522518T1 (de) * 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
CN102060848B (zh) * 2010-12-09 2013-09-18 天津药物研究院 芳香胺取代的嘧啶衍生物的制备及用途
CN102093339B (zh) * 2010-12-09 2013-06-12 天津药物研究院 一类嘧啶衍生物的制备及用途
WO2017004383A1 (en) 2015-06-30 2017-01-05 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof

Also Published As

Publication number Publication date
CN110325528A (zh) 2019-10-11
WO2018115218A1 (en) 2018-06-28
TW201834651A (zh) 2018-10-01
US10882848B2 (en) 2021-01-05
JP7076453B2 (ja) 2022-05-27
US20210070739A1 (en) 2021-03-11
EP3558967B1 (en) 2022-03-02
US20190308955A1 (en) 2019-10-10
JP2020502246A (ja) 2020-01-23
CN110325528B (zh) 2022-10-11
EP3558967A1 (en) 2019-10-30
US11708354B2 (en) 2023-07-25

Similar Documents

Publication Publication Date Title
AR110405A1 (es) Compuestos
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR113929A1 (es) Compuestos heterocíclicos
AR100058A1 (es) DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
AR100702A1 (es) Compuestos inhibidores de quinasa de unión tank
AR107973A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR109296A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
AR109776A1 (es) Compuestos de p2x₃ y/o p2x₂/₃ y métodos
AR108864A1 (es) Agentes antibacterianos
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR101255A1 (es) Derivados de isoindolinona
AR115936A1 (es) Compuestos útiles en terapia del vih
AR102258A1 (es) Compuestos de quinolina y quinazolina
AR119376A1 (es) Compuestos heterocíclicos
AR111252A1 (es) Compuestos de isoxazol carboxamida y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure